CA2086437A1 - Agents thrombolytiques presentant une affinite pour les phospholipides - Google Patents

Agents thrombolytiques presentant une affinite pour les phospholipides

Info

Publication number: CA2086437A1
Authority: CA; Canada
Prior art keywords: compound; conjugate; ann; annexin; urokinase
Prior art date: 1991-05-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002086437A

Other languages

English (en)

Inventor

Jonathan Tait

Kazuo Fujikawa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Washington

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-09

Filing date

1992-05-11

Publication date

1992-11-10

1992-05-11 Application filed by Individual filed Critical Individual

1992-11-10 Publication of CA2086437A1 publication Critical patent/CA2086437A1/fr

Status Abandoned legal-status Critical Current

Links

239000003527 fibrinolytic agent Substances 0.000 title description 4
229960000103 thrombolytic agent Drugs 0.000 title description 3
230000027455 binding Effects 0.000 claims abstract description 17
238000009739 binding Methods 0.000 claims abstract description 17
150000003904 phospholipids Chemical class 0.000 claims abstract description 11
150000001875 compounds Chemical class 0.000 claims abstract 63
239000002243 precursor Substances 0.000 claims abstract 6
238000000034 method Methods 0.000 claims description 17
108090000672 Annexin A5 Proteins 0.000 claims description 15
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 15
102000000412 Annexin Human genes 0.000 claims description 14
108050008874 Annexin Proteins 0.000 claims description 14
102000004121 Annexin A5 Human genes 0.000 claims description 14
108090000623 proteins and genes Proteins 0.000 claims description 12
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
229960005356 urokinase Drugs 0.000 claims description 11
230000001225 therapeutic effect Effects 0.000 claims description 9
108010023197 Streptokinase Proteins 0.000 claims description 7
108010073863 saruplase Proteins 0.000 claims description 7
229960005202 streptokinase Drugs 0.000 claims description 7
102000007625 Hirudins Human genes 0.000 claims description 6
108010007267 Hirudins Proteins 0.000 claims description 6
229940006607 hirudin Drugs 0.000 claims description 6
239000013612 plasmid Substances 0.000 claims description 6
238000010494 dissociation reaction Methods 0.000 claims description 5
230000005593 dissociations Effects 0.000 claims description 5
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 5
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 6
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 6
229960000187 tissue plasminogen activator Drugs 0.000 claims 6
108020001507 fusion proteins Proteins 0.000 claims 5
102000037865 fusion proteins Human genes 0.000 claims 5
238000012217 deletion Methods 0.000 claims 3
230000037430 deletion Effects 0.000 claims 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
239000003085 diluting agent Substances 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
102000015636 Oligopeptides Human genes 0.000 claims 1
108010038807 Oligopeptides Proteins 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
125000000539 amino acid group Chemical group 0.000 claims 1
-1 iodoacetyl groups Chemical group 0.000 claims 1
230000002934 lysing effect Effects 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
102000009123 Fibrin Human genes 0.000 description 17
108010073385 Fibrin Proteins 0.000 description 17
229950003499 fibrin Drugs 0.000 description 17
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 16
210000004369 blood Anatomy 0.000 description 16
239000008280 blood Substances 0.000 description 16
239000002299 complementary DNA Substances 0.000 description 14
239000000047 product Substances 0.000 description 13
239000002253 acid Substances 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
230000000694 effects Effects 0.000 description 9
239000011575 calcium Substances 0.000 description 8
239000012190 activator Substances 0.000 description 7
150000002500 ions Chemical class 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 6
101000652736 Homo sapiens Transgelin Proteins 0.000 description 6
102100031013 Transgelin Human genes 0.000 description 6
230000035602 clotting Effects 0.000 description 6
230000015271 coagulation Effects 0.000 description 6
238000005345 coagulation Methods 0.000 description 6
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 6
125000002346 iodo group Chemical group I* 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
206010053567 Coagulopathies Diseases 0.000 description 4
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 4
102000013566 Plasminogen Human genes 0.000 description 4
108010051456 Plasminogen Proteins 0.000 description 4
DXYQIGZZWYBXSD-JSGCOSHPSA-N Trp-Pro Chemical group O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(O)=O DXYQIGZZWYBXSD-JSGCOSHPSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
108010084932 tryptophyl-proline Proteins 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000002537 thrombolytic effect Effects 0.000 description 3
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000518994 Conta Species 0.000 description 2
241000501458 Cultus Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108060005987 Kallikrein Proteins 0.000 description 2
102000001399 Kallikrein Human genes 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000235648 Pichia Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
235000003969 glutathione Nutrition 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
101150019416 trpA gene Proteins 0.000 description 2
PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
241001233887 Ania Species 0.000 description 1
102100034283 Annexin A5 Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
241000697872 Bactria Species 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
241001212017 Brana Species 0.000 description 1
241000736839 Chara Species 0.000 description 1
241000725101 Clea Species 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241001044073 Cypa Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
244000228957 Ferula foetida Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150069554 HIS4 gene Proteins 0.000 description 1
241000592718 Ibla Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000235395 Mucor Species 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
101100042676 Mus musculus Skap2 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
208000003629 Rupture Diseases 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000610375 Sparisoma viride Species 0.000 description 1
241001494106 Stenotomus chrysops Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
241000906446 Theraps Species 0.000 description 1
108010076830 Thionins Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
241001547816 Thrombus Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
235000019994 cava Nutrition 0.000 description 1
229930184188 cephalinone Natural products 0.000 description 1
238000010276 construction Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
208000014674 injury Diseases 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
101150085091 lat-2 gene Proteins 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
230000010287 polarization Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA002086437A 1991-05-09 1992-05-11 Agents thrombolytiques presentant une affinite pour les phospholipides Abandoned CA2086437A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69736491A	1991-05-09	1991-05-09
US697,364		1991-05-09

Publications (1)

Publication Number	Publication Date
CA2086437A1 true CA2086437A1 (fr)	1992-11-10

Family

ID=24800848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002086437A Abandoned CA2086437A1 (fr)	1991-05-09	1992-05-11	Agents thrombolytiques presentant une affinite pour les phospholipides

Country Status (5)

Country	Link
EP (1)	EP0538459A4 (fr)
JP (1)	JPH05508664A (fr)
CA (1)	CA2086437A1 (fr)
TW (1)	TW239869B (fr)
WO (1)	WO1992019279A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69433343D1 (de) *	1993-12-07	2003-12-24	Neorx Corp	Pretargeting verfahren und mitteln
ATE237366T1 (de) *	1994-01-24	2003-05-15	Neorx Corp	Radioaktiv-markierte annexine
US20030220233A1 (en)	1994-01-24	2003-11-27	Neorx Corporation	Radiolabeled annexins
US5968477A (en) *	1994-01-24	1999-10-19	Neorx Corporation	Radiolabeled annexin conjugates with hexose and a chelator
EP1364964A1 (fr) *	1994-06-16	2003-11-26	Neorx Corporation	Conjugués radiomarques d'annexine-galactose
EP0765166B1 (fr) *	1994-06-16	2003-05-21	Neorx Corporation	Conjugues radiomarques d'annexine-galactose
WO1996017618A1 (fr) *	1994-12-07	1996-06-13	Neorx Corporation	Conjugues groupes annexine-galactose radiomarques
JPH10512852A (ja) *	1994-12-07	1998-12-08	ネオルクスコーポレイション	放射性標識化アネキシン−ガラクトースクラスター複合体
HUP0001261A3 (en)	1997-04-30	2001-11-28	Univ Washington Seattle	Method of imaging cell death in vivo
US6511829B1 (en) *	1997-10-09	2003-01-28	The Regents Of The University Of California	GFP-annexin fusion proteins
FR2784106B1 (fr)	1998-10-02	2002-04-19	Commissariat Energie Atomique	Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US7645739B2 (en)	2001-02-21	2010-01-12	Alavita Pharmaceuticals, Inc.	Modified annexin compositions and methods of using same
US7635676B2 (en)	2001-02-21	2009-12-22	Alavita Pharmaccuticals, Inc.	Modified annexin proteins and methods for their use in organ transplantation
EP1839670A3 (fr) *	2001-02-21	2009-11-11	Alavita Pharmaceuticals, Inc.	Protéines d'annexine modifiées et leur utilisation contre la thrombose
US7635680B2 (en)	2001-02-21	2009-12-22	Alavita Pharmaceuticals, Inc.	Attenuation of reperfusion injury
CA2442382A1 (fr)	2001-04-03	2002-10-17	Theseus Imaging Corporation	Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
US6726895B2 (en)	2001-04-03	2004-04-27	Board Of Trustees Of The Leland Stanford Junior University	Method of imaging cell death in vivo
FR2841557B1 (fr) *	2002-07-01	2005-12-09	Commissariat Energie Atomique	Peptides ayant une affinite pour un phospholipide et utilisations
FR2841558B1 (fr)	2002-07-01	2004-08-13	Commissariat Energie Atomique	Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2856069A1 (fr) *	2003-06-10	2004-12-17	Bionexis	Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
US20190248920A1 (en)	2016-09-23	2019-08-15	Csl Limited	Coagulation factor binding proteins and uses thereof
TW202146042A (zh) *	2020-03-06	2021-12-16	瑞典商阿斯特捷利康公司	用於治療動脈和靜脈血栓形成的協同且靶向的組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT87083B (pt) *	1987-03-28	1992-07-31	Boehringer Ingelheim Int	Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US5225537A (en) *	1989-12-29	1993-07-06	Zymogenetics, Inc.	Methods for producing hybrid phospholipid-binding proteins
AU8492991A (en) *	1990-10-04	1992-04-28	New England Deaconess Hospital Corporation	Soluble thrombogenesis inhibitor conjugates

1992
- 1992-05-11 EP EP19920913004 patent/EP0538459A4/en not_active Ceased
- 1992-05-11 WO PCT/US1992/003960 patent/WO1992019279A1/fr not_active Ceased
- 1992-05-11 CA CA002086437A patent/CA2086437A1/fr not_active Abandoned
- 1992-05-11 JP JP92512046A patent/JPH05508664A/ja active Pending
- 1992-07-17 TW TW081105670A patent/TW239869B/zh active

Also Published As

Publication number	Publication date
WO1992019279A1 (fr)	1992-11-12
TW239869B (fr)	1995-02-01
EP0538459A1 (fr)	1993-04-28
EP0538459A4 (en)	1993-06-16
JPH05508664A (ja)	1993-12-02

Publication	Publication Date	Title
CA2086437A1 (fr)	1992-11-10	Agents thrombolytiques presentant une affinite pour les phospholipides
Coller et al.	1992	Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions.
DE69015182T2 (de)	1995-05-24	Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.
Loughrey et al.	1987	A non-covalent method of attaching antibodies to liposomes
US5308617A (en)	1994-05-03	Protein heparin conjugates
Maeda et al.	1987	Fibrinogen-induced erythrocyte aggregation: erythrocyte-binding site in the fibrinogen molecule
Knudsen	1990	Acyl-CoA-binding protein (ACBP) and its relation to fatty acid-binding protein (FABP): an overview
JPH01503515A (ja)	1989-11-30	脈管抗凝固性タンパク質、それらをコードするｄｎａ、それらの製造方法及びそれらの使用
JPS60174724A (ja)	1985-09-09	蛋白質複合体
Hubbard et al.	1989	Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site.
EP0151308B1 (fr)	1988-05-11	Complexe d'urokinase adsorbable par la fibrine et procédé de préparation
DE69627191T2 (de)	2004-01-08	Bradikininanaloge als selektive thrombininhibitoren
EP0146050B1 (fr)	1990-07-04	Activateur de plasminogène à site sélectif et son procédé de préparation et d'application
US4996050A (en)	1991-02-26	Fibrinolytic activity enhancer
CA1337796C (fr)	1995-12-26	Conjugues d'activateur de plasminogene et d'heparine
JP2000505300A (ja)	2000-05-09	組換えリボヌクレアーゼタンパク質
US5474766A (en)	1995-12-12	Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
Nakano et al.	1998	Characterization of soluble thrombomodulin fragments in human urine
US20080317761A1 (en)	2008-12-25	Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
Utsumi et al.	1991	Preparation and characterization of liposomal-lipophilic tumor necrosis factor
EP0942996B1 (fr)	2007-01-03	Agents thrombolytiques a activite antithrombotique
US5336493A (en)	1994-08-09	Superoxide dismutase-catalase conjugates
JPS6360938A (ja)	1988-03-17	修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
JPH06507158A (ja)	1994-08-11	糖蛋白質および核酸結合物質を含む新しい結合体
JPS60184026A (ja)	1985-09-19	組織プラスミノ−ゲン・アクチベ−タ−の溶解補助方法

Legal Events

Date	Code	Title	Description
1998-05-11	FZDE	Discontinued
2023-05-26	FZDE	Discontinued	Effective date: 19980511